With a 2024 valuation of USD 2.3 Bn, the global Multicancer Screening Market is projected to accelerate to USD 9.7 Bn by 2034, demonstrating a CAGR of 15.4% during the 2025–2034 forecast window.
Multicancer Screening covers key industry insights & findings from the report:
The global ageing population is more susceptible to cancer, driving the need for effective screening methods. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Market momentum is fueled by expanding interest in advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region projected to deliver the strongest growth trajectory through the forecast period, fueled by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Multicancer Screening Market Snapshot
Chapter 4. Global Multicancer Screening Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Application Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Test Type Estimates & Trend Analysis
5.1. by Test Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Test Type:
5.2.1. Laboratory Developed Tests (LDTs)
5.2.2. In-Vitro Diagnostics (IVDs)
Chapter 6. Market Segmentation 2: by Technology Estimates & Trend Analysis
6.1. by Technology & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Technology:
6.2.1. Next-Generation Sequencing (NGS)
6.2.2. Polymerase Chain Reaction (PCR)
6.2.3. Immunohistochemistry (IHC)
6.2.4. Fluorescence In-Situ Hybridization (FISH)
6.2.5. Other Technologies
Chapter 7. Market Segmentation 3: by Sample Estimates & Trend Analysis
7.1. by Sample & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Sample:
7.2.1. Tissue
7.2.2. Blood
7.2.3. Saliva and Buccal Swab
7.2.4. Others
Chapter 8. Market Segmentation 4: by Method Estimates & Trend Analysis
8.1. by Method & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Method:
8.2.1. DNA
8.2.2. RNA
8.2.3. Proteins
Chapter 9. Market Segmentation 5: by Cancer Type Estimates & Trend Analysis
9.1. by Cancer Type & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Cancer Type:
9.2.1. Breast and Gynecologic
9.2.2. Gastrointestinal
9.2.3. Endocrine
9.2.4. Genitourinary
9.2.5. Skin
9.2.6. Brain/Nervous System
9.2.7. Sarcoma
9.2.8. Hematological Malignancies
9.2.9. Lung
9.2.10. Head and Neck
9.2.11. Other Cancer Types
Chapter 10. Market Segmentation 6: by Application Estimates & Trend Analysis
10.1. by Application& Market Share, 2024 & 2034
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Application:
10.2.1. Clinical
10.2.2. Research
Chapter 11. Market Segmentation 7: by End User Estimates & Trend Analysis
11.1. by End User & Market Share, 2024 & 2034
11.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End User:
11.2.1. Hospitals
11.2.2. Diagnostic and Clinical Laboratories
11.2.3. Academic and Research Institutions
11.2.4. Other End Users
Chapter 12. Multicancer Screening Market Segmentation 9: Regional Estimates & Trend Analysis
12.1. North America
12.1.1. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2021-2034
12.1.2. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.1.3. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Sample, 2021-2034
12.1.4. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
12.1.5. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2021-2034
12.1.6. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.1.7. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
12.1.8. North America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
12.2. Europe
12.2.1. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2021-2034
12.2.2. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.2.3. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Sample, 2021-2034
12.2.4. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
12.2.5. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2021-2034
12.2.6. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.2.7. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
12.2.8. Europe Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
12.3. Asia Pacific
12.3.1. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2021-2034
12.3.2. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.3.3. Asia-Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Sample, 2021-2034
12.3.4. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
12.3.5. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2021-2034
12.3.6. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.3.7. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
12.3.8. Asia Pacific Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
12.4. Latin America
12.4.1. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2021-2034
12.4.2. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.4.3. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Sample, 2021-2034
12.4.4. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
12.4.5. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2021-2034
12.4.6. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.4.7. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
12.4.8. Latin America Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
12.5. Middle East & Africa
12.5.1. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2021-2034
12.5.2. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.5.3. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Sample, 2021-2034
12.5.4. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Method, 2021-2034
12.5.5. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2021-2034
12.5.6. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.5.7. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
12.5.8. Middle East & Africa Multicancer Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 13. Competitive Landscape
13.1. Major Mergers and Acquisitions/Strategic Alliances
13.2. Company Profiles
13.2.1. Agilent Technologies, Inc.
13.2.2. Atara Biotherapeutics, Inc.
13.2.3. Burning Rock DX
13.2.4. Danaher Corporation
13.2.5. Exact Sciences Corporation
13.2.6. F. Hoffmann-La Roche Ltd
13.2.7. Fulgent Genetics.
13.2.8. Genecast Biotechnology Co., Ltd
13.2.9. Guardant Health, Inc.
13.2.10. Illumina, Inc.
13.2.11. Konica Minolta, Inc.
13.2.12. Laboratory Corporation of America Holdings.
13.2.13. Myriad Genetics, Inc.
13.2.14. Tempus
13.2.15. Thermo Fisher Scientific Inc.
13.2.16. Other Prominent Players